Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
American Journal of Medical Genetics
|
February 13, 2002
Association studies of the HOPA dodecamer duplication variant in different subtypes of autism
Kim S Beyer, Sabine M Klauck, Axel Benner, et al.
Biochemical and Biophysical Research Communications
|
August 11, 2006
Magicin associates with the Src-family kinases and is phosphorylated upon CD3 stimulation
Ming-Fen Lee, Roberta L Beauchamp, Kim S Beyer, et al.
American Journal of Human Genetics
|
March 9, 2002
A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome
Sabine M Klauck, Susan Lindsay, Kim S Beyer, et al.
Human Genetics
|
October 18, 2002
Mutation analysis of the coding sequence of the MECP2 gene in infantile autism
Kim S Beyer, Francesca Blasi, Elena Bacchelli, et al.
The Journal of Biological Chemistry
|
September 13, 2007
Mediator subunit MED28 (Magicin) is a repressor of smooth muscle cell differentiation
Kim S Beyer, Roberta L Beauchamp, Ming-Fen Lee, et al.
ACS Medicinal Chemistry Letters
|
August 27, 2016
Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket
Clemens Scheufler, Henrik Möbitz, Christoph Gaul, et al.
ACS Medicinal Chemistry Letters
|
December 21, 2019
New Potent DOT1L Inhibitors for <i>in Vivo</i> Evaluation in Mouse
Frédéric Stauffer, Andreas Weiss, Clemens Scheufler, et al.
American Journal of Medical Genetics. Part A
|
April 15, 2009
FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome
Bärbel Felder, Bernhard Radlwimmer, Axel Benner, et al.
ACS Medicinal Chemistry Letters
|
March 25, 2017
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach
Henrik Möbitz, Rainer Machauer, Philipp Holzer, et al.
ACS Medicinal Chemistry Letters
|
August 27, 2016
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach
Chao Chen, Hugh Zhu, Frédéric Stauffer, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
American Journal of Medical Genetics
|
February 13, 2002
Association studies of the HOPA dodecamer duplication variant in different subtypes of autism
Kim S Beyer, Sabine M Klauck, Axel Benner, et al.
Biochemical and Biophysical Research Communications
|
August 11, 2006
Magicin associates with the Src-family kinases and is phosphorylated upon CD3 stimulation
Ming-Fen Lee, Roberta L Beauchamp, Kim S Beyer, et al.
American Journal of Human Genetics
|
March 9, 2002
A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome
Sabine M Klauck, Susan Lindsay, Kim S Beyer, et al.
Human Genetics
|
October 18, 2002
Mutation analysis of the coding sequence of the MECP2 gene in infantile autism
Kim S Beyer, Francesca Blasi, Elena Bacchelli, et al.
The Journal of Biological Chemistry
|
September 13, 2007
Mediator subunit MED28 (Magicin) is a repressor of smooth muscle cell differentiation
Kim S Beyer, Roberta L Beauchamp, Ming-Fen Lee, et al.
ACS Medicinal Chemistry Letters
|
August 27, 2016
Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket
Clemens Scheufler, Henrik Möbitz, Christoph Gaul, et al.
ACS Medicinal Chemistry Letters
|
December 21, 2019
New Potent DOT1L Inhibitors for <i>in Vivo</i> Evaluation in Mouse
Frédéric Stauffer, Andreas Weiss, Clemens Scheufler, et al.
American Journal of Medical Genetics. Part A
|
April 15, 2009
FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome
Bärbel Felder, Bernhard Radlwimmer, Axel Benner, et al.
ACS Medicinal Chemistry Letters
|
March 25, 2017
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach
Henrik Möbitz, Rainer Machauer, Philipp Holzer, et al.
ACS Medicinal Chemistry Letters
|
August 27, 2016
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach
Chao Chen, Hugh Zhu, Frédéric Stauffer, et al.
Page
of 3